Literature DB >> 18588596

Temporal cortex dopamine D2/3 receptor binding in major depression.

Soili M Lehto1, Jyrki Kuikka, Tommi Tolmunen, Jukka Hintikka, Heimo Viinamäki, Ritva Vanninen, Kaisa Haatainen, Heli Koivumaa-Honkanen, Kirsi Honkalampi, Jari Tiihonen.   

Abstract

The aim of this study was to assess the dopamine function of the temporal cortex in major depressive disorder using [(123)I]epidepride to image D(2/3) receptor binding sites. Ten major depressives and 10 healthy controls were selected from a general population sample for single-photon emission computed tomography imaging. Among the major depressives there was a strong bilateral correlation between the scores on the 21-item Hamilton Depression Rating Scale and D(2/3) receptor binding. Dopaminergic abnormalities may be present in the temporal cortices of major depressives.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18588596     DOI: 10.1111/j.1440-1819.2008.01814.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  3 in total

1.  Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins.

Authors:  Ferdinando Squitieri; Sara Orobello; Milena Cannella; Tiziana Martino; Pantaleo Romanelli; Giampiero Giovacchini; Luigi Frati; Luigi Mansi; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-11       Impact factor: 9.236

2.  Neurocognitive Predictors of Response in Treatment Resistant Depression to Subcallosal Cingulate Gyrus Deep Brain Stimulation.

Authors:  Shane J McInerney; Heather E McNeely; Joseph Geraci; Peter Giacobbe; Sakina J Rizvi; Amanda K Ceniti; Anna Cyriac; Helen S Mayberg; Andres M Lozano; Sidney H Kennedy
Journal:  Front Hum Neurosci       Date:  2017-02-24       Impact factor: 3.169

3.  In vivo absolute quantification of striatal and extrastriatal D2/3 receptors with [123I]epidepride SPECT.

Authors:  Stergios Tsartsalis; Benjamin B Tournier; Philippe Millet
Journal:  EJNMMI Res       Date:  2020-06-16       Impact factor: 3.138

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.